Oncology drugs provided the clearest examples, with UGT1A1 variation predicting irinotecan toxicity and dihydropyrimidine dehydrogenase (DPYD) deficiency influencing fluoropyrimidine intolerance. Here, DPYD is linked to hyperinsulinemic hypoglycemia, familial, 4.